Atrial fibrillation (AF) is a common cardiac arrhythmia associated with high mortality and morbidity. Current treatments of AF have limited efficacy and considerable side effects. Histone deacetylases (HDACs) play critical roles in the pathophysiology of cardiovascular diseases and contribute to the genesis of AF. Therefore, HDAC inhibition may prove a novel therapeutic strategy for AF through upstream therapy and modifications of AF electrical and structural remodeling. In this review, we provide an update of the knowledge of the effects of HDACs and HDAC inhibitors on AF, and dissect potential underlying mechanisms.
ASJC Scopus subject areas
Lkhagva, B., Kao, Y. H., Chen, Y. C., Chao, T. F., Chen, S. A., & Chen, Y. J. (2016). Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2016.04.034